4.5 Article

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study

期刊

BLOOD CANCER JOURNAL
卷 12, 期 9, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41408-022-00732-3

关键词

-

资金

  1. International Myeloma Foundation
  2. Amgen
  3. Celgene
  4. Icelandic Center for Research (Rannis)
  5. Sylvester Comprehensive Cancer Center Core Grant [P30 CA240139]
  6. Paula and Rodger Riney Foundation
  7. Memorial Sloan Kettering Cancer Center Core Grant [P30 CA008748]
  8. Black Swan Research Initiative by the International Myeloma Foundation
  9. European Research Council
  10. Icelandic Center for Research
  11. Icelandic Cancer Society
  12. University of Iceland
  13. Landspitali-The National University Hospital

向作者/读者索取更多资源

This study aimed to establish a reference interval for serum free light chain (FLC) in patients with chronic kidney disease (CKD). Using a large prospective population-based cohort, new reference intervals for FLC values based on estimated glomerular filtration rate (eGFR) were proposed. The current reference intervals were found to be inaccurate in CKD patients, suggesting the need for implementation of the new eGFR-based reference intervals.
Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic kidney disease (CKD). A total of 75422 participants of the iStopMM study were screened with serum FLC, serum protein electrophoresis and immunofixation. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Central 99% reference intervals were determined, and 95% confidence intervals calculated. Included were 6461 (12%) participants with measured FLCs, eGFR < 60 mL/min/1.73 m(2), not receiving renal replacement therapy, and without evidence of monoclonality. Using current reference intervals, 60% and 21% had kappa and lambda FLC values outside the normal range. The FLC ratio was outside standard reference interval (0.26-1.65) in 9% of participants and outside current kidney reference interval (0.37-3.10) in 0.7%. New reference intervals for FLC and FLC ratio were established. New reference intervals for the FLC ratio were 0.46-2.62, 0.48-3.38, and 0.54-3.30 for eGFR 45-59, 30-44, and < 30 mL/min/1.73 m(2) groups, respectively. The crude prevalence of LC-MGUS in CKD patients was 0.5%. We conclude that current reference intervals for FLC and FLC ratio are inaccurate in CKD patients and propose new eGFR based reference intervals to be implemented.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据